ESR1 and neoplasm: In ER-positive breast cancer, co-treatment with DGY-09-192 and the ERα degrader fulvestrant led to complete inhibition of cell proliferation and significant tumor regression in ER-positive, FGFR1-amplified patient-derived xenograft models.